# Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan

> **NCT03595709** · PHASE3 · COMPLETED · sponsor: **Yu-Jay Corp.** · enrollment: 50 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** 3-in-1 tablet (EFV 400mg, TDF 300mg, 3TC 300mg)

## Key facts

- **NCT ID:** NCT03595709
- **Lead sponsor:** Yu-Jay Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-06
- **Primary completion:** 2019-03-06
- **Final completion:** 2019-07-16
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03595709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03595709, "Therapeutic Drug Monitoring Study of Reduced-Dose Efavirenz (400 mg) in Combo Tablet for Patients Receiving Atripla With Viral Suppression in Taiwan". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03595709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*